Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
Hsien Hong Lin(Taipei Tzu Chi Hospital), Pei‐Jer Chen(National Taiwan University), Chao‐Wei Hsu, Rong‐Nan Chien(Chang Gung Memorial Hospital), Sheng Lu(First People's Hospital of Yunnan Province), Cheng‐Yuan Peng(China Medical University), Wei Su(University of Hawaiʻi at Mānoa), Shih Jer Hsu(National Formosa University), Yi‐Wen Huang(University of Pisa), Jaw Ching Wu(Taipei Veterans General Hospital), Kuan Chiao Tseng(Efficient Pharma Management (Taiwan)), Tzong Hsi Lee(Far Eastern Memorial Hospital), Wan‐Long Chuang(Kaohsiung Medical University), Sien Sing Yang(Cathay General Hospital), Albert Qin
Cited by 22
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569